Operational and financial results for the period ended september 30, 2020

New york, nov. 19, 2020 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational and financial results for the first quarter ended september 30, 2020 (fy2021).
MESO Ratings Summary
MESO Quant Ranking